The US Food and Drug Administration (FDA) has published its final guidance, Psychedelic Drugs: Considerations for Clinical Investigations, providing clearer direction for Sponsors developing psychedelic
MAC Clinical Research, supporting Initiator Pharma as a full-service CRO, is pleased to announce the successful progression of participant enrolment with half already dosed in
MAC Clinical Research has reached a key milestone in a Phase 1b study sponsored by Newleos Therapeutics investigating NTX-1955, a potential new treatment for Generalised
MAC Clinical Research is pleased to announce positive topline results from AtaiBeckley’s exploratory Phase 2a clinical trial evaluating an investigational therapy in Social Anxiety Disorder
MAC Clinical Research is proud to have partnered with Gilgamesh Pharma in the successful completion of a Phase 2a clinical trial evaluating Blixeprodil (GM-1020), a
By Dr Shoona Vincent, Vice President of Clinical Science at MAC Clinical Research The psychedelic research renaissance is well underway, with clinical trials investigating psilocybin,
The latest update from the MHRA and UK Government shows continued momentum in UK clinical research, with rising trial numbers and new regulatory changes set
Selecting a Contract Research Organisation (CRO) is one of the most important decisions a Sponsor will make in the planning and delivery of any clinical
As the year comes to a close, it’s a good time to pause and look back on everything we’ve achieved together in 2025. It’s been
MAC Clinical Research is proud to support Initiator Pharma as the full-service CRO partner for their upcoming Phase 2a clinical trial, as they take an
